Stay informed with the latest litigation news. Explore now

IP Verse

Use Of Chimeric Antigen Receptor-Modified T Cells To Treat Cancer - EP3214091B1

EP3214091

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Application Number
EP17153799A
Filing Date
Dec 9, 2011
Status
Revoked
Mar 27, 2020
Grant Date
Oct 3, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3215166B9
EP3888674B1
EP3134120B1

Bibliography

The patent EP3214091B1 was granted to The Trustees OF The University OF Pennsylvania on Oct 3, 2018 following the initial filing on Dec 9, 2011 under the application number EP17153799A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

PLASSERAUDJul 3, 2019ADMISSIBLE
MEDECINS DU MONDE ET ALJul 2, 2019ADMISSIBLE
MILTENYI BIOTECJul 2, 2019ADMISSIBLE
PUBLIC EYEJul 2, 2019ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents